- Dr. Neha Pagidipati presented a secondary analysis on gender differences in the results of the PROMISE trial in a featured clinical research session.
- Dr. Paty Guimarães’s moderated poster reported on stroke risk in patients with newly-diagnosed atrial fibrillation from the ARISTOTLE trial
- Dr. Jacob Doll’s survey of patients with coronary artery disease found that nearly all patients wanted to share decision making regarding revascularization or medical therapy with their physicians.
- Dr. Sean Pokorney analyzed the FDA’s Mini-Sentinel pilot project for drug safety surveillance, and found that oral anticoagulants may be underutilized amongst patients with atrial fibrillation
- Dr. Benjamin Steinberg presented an analysis from ORBIT-AF II demonstrating more frequent prescription of targeted oral anticoagulants than warfarin among patients with newly diagnosed atrial fibrillation
- Dr. Larry Jackson’s analysis of ORBIT-AF found a low risk of stroke in patients with low CHA2DS2-VASc scores
- Dr. Chris Fordyce presented data from the RACE CARS program, which demonstrated that a statewide effort to promote early defibrillation and CPR increased the percentage of patients suffering cardiac arrest at home that received bystander CPR at home and improved outcomes
- Dr. Andrew Ambrosy’s secondary analysis of ASCEND-HF examined the correlation between body weight loss and symptoms of congestion in patients with heart failure exacerbations
- Dr. Ann Marie Navar presented research demonstrating that patients routinely overestimate their risk of suffering a cardiovascular event. In another study, an analysis of the PALM registry, Dr. Navar found that many patients reported side effects from statins, but that most patients continued statin therapy despite these symptoms.
Dr. Shochat’s research, presented as a late-breaking clinical trial at ACC.16, demonstrated the efficacy in preventing heart failure exacerbations of guiding therapy with non-invasive measurement of volume status using lung impedance.
Dr. Pagitipati, a DCRI fellow, presented her secondary analysis of the PROMISE trial in a featured clinical research session at ACC.16. Along with her co-authors, she found that, in women, CT angiography is less likely to be positive than functional stress testing, but that if a CTA is positive, it is associated with a greater incidence of cardiovascular events. Her findings were simultaneously published in JACC.
Dr. Kreatsoulas’s research has demonstrated that women’s anginal symptoms are similar to those of men, but that women describe them differently; in an ongoing study, she and colleagues are developing artificial intelligence to predict obstructive coronary artery disease.
Dr. Udell’s soon-to-begin study examines the effect of different strengths of influenza vaccines on cardiopulmonary hospitalizations and mortality in patients with coronary artery disease.
DCRI fellow Dr. Paty Guimarães and Dr. Pamela Douglas discuss Dr. Douglas’s provocative study on differences in job description and compensation between male and female cardiologists.
NEAT-HFpEF randomized patients with heart failure with preserved EF to nitrates or placebo, and used accelerometer data to measure activity levels at home. Patients treated with isosorbide mononitrate had significantly lower activity levels compared to those treated with placebo, and higher doses were associated with less activity.
The highly-anticipated SPRINT trial demonstrated a 25% reduction in cardiovascular events and a 27% reduction in all-cause mortality with strict blood pressure control (SBP < 120) compared to lenient control (SBP < 140).
PROACT-4 was a pragmatic clinical trial examining in-ambulance biomarker measurement to standard care in patients with possible NTE-ACS. Measuring biomarkers in the ambulance reduced the time to disposition by 30 minutes compared to those getting standard care.
Dr. Faroukh’s group presented a patient-level meta-analysis of diabetic patients in COURAGE, BARI-2D, and FREEDOM — trials examining different options for revascularization. The meta-analysis showed that CABG was superior to PCI for reducing clinical outcomes in diabetic patients with double and triple vessel disease, even those without proximal LAD disease.